← SUPERNUS PHARMACEUTICALS, INC. (SUPN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Pharmaceutical Preparations · market cap $2.5B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Supernus Pharmaceuticals (SUPN) is a ~$2.7B market cap specialty pharma company focused on CNS disorders, with 674 employees and a diversified pipeline spanning ADHD, epilepsy, depression, and neurological conditions. The company generates meaningful commercial revenue (~$719M in 2025) but posted a net loss of $39M that year, reflecting elevated R&D investment. The highest-impact near-term catalyst is a Phase 3 readout for SPN-812 (viloxazine extended-release for ADHD) expected around September 2026.
The catalyst path
- 2026-10-15 (est.)Phase 2 · SPN-817imp 7/10
- 2026-11-03 (est.)Earningsimp 5/10
- 2026-12-30 (est.)Phase 2 · BIS-001ERimp 7/10
- 2026-12-31 (est.)Phase 2 · SPN-821 2400 mgimp 7/10
- 2027-08-15 (est.)Phase 2 · SPN-817imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TPM XR | Phase 2 | Epilepsy |
| 400mg SPN-812 | Phase 3 | ADHD |
| SPN-810 (36 mg) | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) |
| SPN-812 | Phase 3 | Attention-Deficit/Hyperactivity Disorder |
| 200mg SPN-812 | Phase 3 | ADHD |
| 2400mg SPN-804 | Phase 3 | Epilepsies, Partial |
| SAGE-718 | Phase 2 | Alzheimer Disease |
| Molindone | Phase 2 | Impulsive Aggression Comorbid With ADHD in Children |
| BIS-001ER | Phase 2 | Focal Impaired Awareness Seizures |
| MYOBLOC | Phase 3 | Sialorrhea |
| SPN-817 | Phase 2 | Focal Onset Seizures |
| IR Viloxazine | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) |
| Oxcarbazepine XR | Phase 3 | Partial Epilepsy |
| SAGE-547 90 μg/kg/h | Phase 3 | Postpartum Depression |
| SAGE-547 60 μg/kg/h | Phase 3 | Postpartum Depression |
| SPN-810 | Phase 2 | Attention Deficit Disorder With Hyperactivity |
| SPN-810 (18 mg) | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) |
| Brexanolone | Phase 3 | Tinnitus |
| 100mg SPN-812 | Phase 3 | Attention-Deficit/Hyperactivity Disorder (ADHD) |
| SAGE-547 | Phase 3 | Postpartum Depression |
Price & technical context
3-month
-12.2%
6-month
-18.0%
12-month
-12.2%
52-wk range
$41.28–$57.00
vs 50-day MA
-5.9%
vs 200-day MA
-12.5%
Realized vol
46.0%
Max drawdown
-27.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SUPN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.